Innoviva Inc (INVA) — closed signal from March 19, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 17, 2026 — +2.5% at the close.
Predicted vs. what happened
What happened
Reached 59% of the predicted growth at its peak, without hitting the target.
The thesis — published March 19, 2026
The company looks promising because management has a clear growth plan for its infectious-disease business, analysts raised their price target, and the company is buying back shares. That mix gives a real chance of a bounce from current low prices. However, trading is light and the company has an uneven earnings history, so wait and size positions small.
Primary drivers
- New infectious-disease business can drive company-specific growth
- Share buybacks support the stock and return cash to holders
- Strong cash versus debt reduces need to raise money
- Low share price raises chance of a substantial rebound
How it played out
INVA: rose 10.7% but missed the target
Lyra published INVA at $22.08 with an 18% expected gain and a $26.05 target. The thesis pointed to growth in the infectious-disease business, share buybacks, strong cash versus debt, and the chance of a rebound from a low share price. It also noted light trading and an uneven earnings history.
Inside the window, INVA peaked at $24.45 on April 20, 2026, a 10.7% gain. That peak stayed below the $26.05 target, so the target was never reached. The stock ended the window at $22.64. The thesis partially played out: the shares rose, but the expected 18% gain did not arrive.
What happened during the window
On May 6, 2026, Innoviva reported first-quarter results, including $34.2 million in U.S. product sales for its infectious-disease business. On June 16, 2026, its subsidiary announced a distribution and licensing agreement with Dr. Reddy's for XACDURO in several international markets.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.